DEA Temporarily Schedules Dangerous 7-OH and Related Substances

On July 1, 2026, the U.S. Drug Enforcement Administration (DEA) filed its intent to temporarily place 7-hydroxymitagynine (7-OH) and three related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16) into Schedule I of the Controlled Substances Act (CSA). This action, supported by HHS and FDA, targets highly concentrated, synthetic 7-OH products that pose a growing threat to public safety and health, making their manufacture, distribution, sale, and possession subject to criminal provisions.

Context

7-hydroxymitagynine is a potent derivative of kratom, a plant that has gained popularity for its psychoactive effects. The DEA's move comes amid rising reports of adverse health effects linked to synthetic versions of kratom compounds. The support from the Department of Health and Human Services and the Food and Drug Administration underscores a coordinated federal effort to address the issue.

Why it matters

The DEA's decision to temporarily schedule 7-hydroxymitagynine and related substances is significant as it addresses increasing concerns over public safety and health risks associated with these synthetic drugs. By classifying them as Schedule I substances, the DEA aims to curb their availability and mitigate potential harm to consumers. This action reflects a growing recognition of the dangers posed by unregulated synthetic drugs in the market.

Implications

The scheduling of these substances may lead to a decrease in their availability, potentially reducing health risks associated with their use. Law enforcement agencies will have new tools to combat the illegal distribution of these drugs. However, users may turn to alternative substances, which could pose new challenges for public health and safety.

What to watch

In the near term, stakeholders will be monitoring the implementation of the scheduling and its impact on the market for these substances. The response from manufacturers and distributors of synthetic drugs will also be critical, as they may seek to adapt to the new regulations. Additionally, public health agencies may increase efforts to educate consumers about the risks associated with these substances.